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Poster Session-I 53presentation, treatment and risk-factors. AVN was defined as the
presence of joint symptoms with confirmatory radiological findings
on X-ray, CT or MRI at any time after HCT. Among 3527 HCT
recipients from 1990–2007, 73 (2.1%) cases of post-HCT AVN
were identified; of these, 8 (0.7%) occurred after autologous and
65 (2.7%) after allogeneic HCT (sibling 33, unrelated 19, umbilical
cord blood 13). Median age at HCT for cases was 29 (range, 4–60)
years and included 23% pediatric recipients (\18 years). Median fol-
lowup was 7 (range, 1–16) years. Myeloablative conditioning was
used in 74% and 77% received total body irradiation (TBI). Acute
and chronic graft-versus-host disease (GVHD) occurred in 69%
and 65%, respectively. Use of prednisone (or equivalent) was very
prevalent; 8%had receivedno prednisone, 23%had received a cumu-
lative dose of #0.5 mg/kg/day, and 69% had received .0.5 mg/kg/
day prior to diagnosis of AVN. AVN affected 155 joints in these 73
patients (median number of joints involved 2 [range, 1–6]) and was
diagnosed at a median of 18 months (interquartile range 11–33
months) post-HCT. Proximal femur (54%) and distal femur (36%)
were the most common sites. Association Research Circulation
Osseous stage, which classifies progressively worsening radiological
abnormalities and amount of bone involvement from stage 0–4,
could be assigned for 52 cases; of these, stage 3 or 4 (that requires sur-
gical intervention) was present in 60%. Thirty-five (48%) received
surgical treatment for AVN, among which joint replacement was
performed in 31 patients. Risk factor analysis was performed using
a randomly selected cohort of 148 HCT recipients frequency
matched by age, gender and year of HCT and with no joint symp-
toms. Risk of AVN was higher in allogeneic HCT recipients (odds
ratio (OR) 2.7 (95%CI, 1.2–6.2), P5 0.01) andwith exposure to cor-
ticosteroids (OR 15.9 (6.5–39.1), p\ 0.01); diagnosis, conditioning
intensity and use of TBI did not increase its risk. In conclusion, AVN
is a relatively rare complication of HCT, typically occurs within the
first 3 years after HCT, presents with advanced stages and frequently
requires surgical management. Allogeneic HCT recipients, espe-
cially those exposed to corticosteroids, are at highest risk and may
benefit from screening for early detection and treatment to avoid
joint replacement surgery.139
DIAGNOSIS OF MENTAL HEALTH DISORDER DOES NOT EFFECT
OUTCOME IN ALLOGENEIC BONE MARROW TRANSPLANT
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Background: Psychiatric disturbance before allogeneic stem cell
transplant (allo-SCT) has been associated with worse survival and
quality of life and is used in predictive indices for transplant out-
come.
Methods:We report a retrospective study that analyzed 142 pa-
tients who underwent fully ablative allo-SCT between January
2005 and June 2008. Patients with mental health disorder
(MHDx) were identified from pre-transplant psychosocial assess-
ment and physician evaluation before transplant. Patients were as-
signed MHDx if they were taking psychotropic medication or
specific MHDx was documented. Wilcoxon rank sum and Chi-
square tests were used to compare patients withMHDx to patients
without MHDx. Outcomes between these groups were estimated
using the Kaplan-Meier method via the log rank test.
Results: We identified 41 patients with MHDx and 101 patients
without. The Wilcoxon rank sum test analysis showed that patients
with MHDx had a significantly longer period from diagnosis to
transplant (P 5 0.001). Patients with MHDx had an increased inci-
dence of acute graft versus host disease (AGVHD) (P 5 0.003),
but not chronic graft versus host disease (CGVHD) (P 5 0.30).
Kaplan-Meier analysis showed no significant statistical difference
in Relapse Mortality (RM) (0.31), Non-Relapse Mortality (NRM)
(P 5 0.41) or Overall Survival (OS) (P 5 0.99). (See table below.)
One and two-year survival for patients with MHDx (56.2% and
47.2% respectively) and without MHDx (57.2% and 44.2% respec-
tively) were not statistically significant.
Conclusion: Identifying comorbidities that have an impact on
post-transplant survival is crucial to improving transplant outcome.
While this study shows no statistical association betweenMHDx andOS, RM or NRM it demonstrates a significant association of MHDx
on time period from diagnosis to transplant and incidence of
AGVHD. Identifying patients with MHDx early in pre-transplant
staging and initiating appropriate treatment might reduce time to
transplant and AGVHD. Providing targeted psychosocial services
could lead to an overall improved quality of life. This study did
not indicate that MHdx leads to worse outcome. Further investiga-
tion into pre-transplant MHdx and its role in pre-transplant care
as well as in transplant is warranted.
No MHD MHDx P-valueMonths from Diagnosis to
Transplant (mean 1SD)9.9 1 14.6 19.1 1 23.0 0.001AGVHD 59 / 101 (58.4%) 33 / 41 (80.5%) 0.003
CGVHD 33 / 101 (32.7%) 9 / 41 (22.0%) 0.30
Non-Relapse Mortality 28 / 101 (27.7%) 14 / 41 (34.1%) 0.41
Relapse Mortality 22 / 101 (21.8%) 5 / 41 (12.2%) 0.31
Overall Survival 51 / 101 (51.5%) 22 / 41 (53.7%) 0.99140
ALLELIC VARIATION IN TP53 AND MDM2 DNA REPAIR GENES CONSTI-
TUTE GENETIC RISK FACTORS FOR LONG-TERM SURVIVAL IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Dupont, B.1, Malkki, M.2, Gooley, T.2, Wang, H.2, Zhao, L.P.2,
Bojesen, S.E.3, Petersdorf, E.W.2, Hansen, J.A.2 1Memorial Sloan Ketter-
ing Cancer Center, New York, NY; 2Fred Hutchinson Cancer Reserch
Center, Seattle, WA; 3Herlev University Hospital, Herlev, Denmark
The p53 tumor suppressor pathway plays a major role in tumor
development and cell survival. Germline single nucleotide poly-
morphisms (SNP)s in codon 72 of TP53 (Arg72Pro; rs1042522)
and in the promoter region of the ubiquitin ligase MDM2 (-309;
rs2279744) influence apoptotic activity in response to cellular
stress. In vitro studies have demonstrated that cells homozygous
for Arg72 in p53 have significantly increased apoptotic activity in
response to cellular stress, while cells homozygous for Pro72
have increase in cell cycle arrest and DNA repair. We recently in-
vestigated the impact of these two SNPs on survival after transplan-
tation from HLA 10/10 matched unrelated donors. In brief,
analysis of samples and clinical outcome data contributed by the
National Marrow Donor Program Research Sample Repository
and by the Center for International Blood and Marrow Transplant
Research, respectively, demonstrated that patients with two p53
72Pro alleles and at least one copy of the MDM2-309 G allele
had an increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.41). We now re-
port the results of a second independent cohort of donor-recipient
pairs tested for the same p53 and MDM2 SNPs. All patients were
treated at the Fred Hutchinson Cancer Research Center and repre-
sented 731 related and 669 unrelated pairs including HLAmatched
and mismatched cases. We find that patients with two p53 72Pro
alleles and at least one copy of theMDM2-309 G allele had a signif-
icant increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.35). These results
are consistent with our hypothesis that the combination of recipient
genotypes for p53 Arg72/Pro and SNP -309 MDM2 affects post
transplantation survival. Detailed analysis of other clinical outcome
data are currently in progress.141
TASTE DISORDERS AND ORAL CLINIC EVALUATION IN PATIENTS SUBMIT-
TED TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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Graft versus host disease can affect the oral cavity leading to mu-
cosal salivary gland damages and causing change in taste perception.
